Nano Dimension Announces Proposed Merger with Infinite Epigenetics: Key Terms and Investor Implications
Nano Dimension Ltd. (Nasdaq: NNDM) has published a detailed term sheet outlining its proposal for a business combination with Infinite Epigenetics, Inc., a Delaware-based corporation. The proposed deal, if executed, stands to significantly reshape both companies, with implications for shareholders, share valuations, and future corporate strategy.
Key Points of the Proposed Transaction
- Transaction Structure: Nano Dimension intends to acquire 100% of Infinite Epigenetics through a reverse triangular merger or direct stock purchase, with Infinite becoming a wholly owned subsidiary. The structure aims for tax efficiency, including qualifying as a tax-free reorganization under Section 368 of the Internal Revenue Code.
- Ownership and Exchange Ratio: At closing, Infinite shareholders (including option, warrant, and convertible note holders) will receive Nano common stock based on an exchange ratio determined by mutually agreed valuations. Specifically:
- Infinite’s mutually agreed valuation: \$890 million (less a premium)
- Nano’s valuation: sum of net cash at closing, a 20% premium to net cash, and the value of Essemtec (\$20 million) plus other assets.
- Ownership percentages will be calculated based on these valuations, with Infinite holders potentially becoming the majority shareholders if their stake exceeds 55% post-closing.
- Conversion of Equity Awards: Infinite options, restricted stock units, and warrants will convert into equivalent Nano instruments, retaining vesting and exercise schedules.
- Net Cash Definition: Net cash is defined in detail, including cash, marketable securities, receivables, deposits, minus liabilities, debts, transaction costs, lease obligations, employee-related liabilities, litigation contingencies, and taxes, plus prepaid expenses and restricted cash, and net proceeds from legacy asset dispositions.
- Nano Legacy Assets CVR Spin: Nano will establish a liquidation trust/Spinco for its legacy assets, with proceeds from asset sales distributed via Contingent Value Rights (CVRs) exclusively to pre-closing Nano shareholders.
- Board Composition: Post-merger, the combined board will have 7 directors—Infinite will designate 5 if its ownership exceeds 55%, or 4 otherwise. Committee composition will comply with Nasdaq rules.
- Share Issuance: Nano shares issued in the merger will be registered on Form S-4 and listed on Nasdaq.
- Shareholder Approval: Nano will seek shareholder approval via proxy statements and registration filings. Executive officers and directors must sign support agreements (agreeing to vote in favor, no-shop, no-talk obligations, and transfer restrictions).
- Deal Protections and Break Fees:
- Break fee of \$10 million (2.5% of Nano equity valuation) payable by Nano to Infinite under specific failure scenarios.
- Break fee escrow: Nano must deposit the break fee in escrow with a mutually selected third-party agent.
- Other protections: No-shop provisions, fiduciary duty exit rights, and provisions for expense reimbursement if the definitive agreement is not executed.
- Lock-Ups: Executive officers and board members of the combined company, as well as major investors from both companies, will be subject to a 180-day lock-up.
- Senior Management: Composition of the post-merger senior management team will be determined collaboratively.
- Exclusivity: 30-day exclusivity period prohibiting both parties from soliciting or negotiating alternative acquisition proposals.
- Expense Reimbursement: If the merger agreement is not signed by the EGM date (Nano’s Extraordinary General Meeting), Nano will reimburse Infinite up to \$3 million in documented expenses.
- Confidentiality: The term sheet and related negotiations are subject to mutual confidentiality obligations.
Price-Sensitive and Shareholder-Relevant Details
- Potential Majority Control Shift: Infinite shareholders could become the majority owners of Nano, fundamentally changing control and governance.
- Legacy Asset Spin-Off: Pre-merger Nano shareholders retain economic interests in legacy assets via CVRs, which could deliver future value independent of the merged company’s performance.
- Break Fee and Escrow: The mandatory \$10 million break fee escrow is a significant financial commitment by Nano and serves as a strong signal of deal seriousness.
- Lock-Up Agreements: Restrictions on major shareholders and insiders may impact share liquidity and supply post-merger.
- Board and Management Changes: Potential for substantial changes in board composition and senior management, which could affect strategic direction.
- Shareholder Vote Requirement: Shareholders must approve the deal; failure to do so could trigger break fees and expense reimbursements, potentially impacting Nano’s cash position.
- Tax-Free Status: Confirmation that the merger is tax-free for Infinite shareholders is a key factor, potentially affecting after-tax proceeds for investors.
- No Post-Closing Recourse: Representations and warranties will not survive closing, with no price adjustments or escrow for breaches—investors should note the finality of the deal terms.
- Exclusivity Period: For 30 days, neither party can entertain alternative proposals, reducing deal risk but also limiting flexibility.
Potential Share Price Implications
This proposed merger is highly significant and could materially impact Nano Dimension’s share price. The prospect of Infinite Epigenetics shareholders gaining majority control, the spin-off of legacy assets, and the detailed deal protections (including a substantial break fee) all represent major changes. Investors should closely monitor developments, especially as the shareholder vote and regulatory approvals approach.
Shareholders should be aware of:
- The possibility of dilution if Infinite holders become majority owners
- The value of legacy assets being distributed separately via CVRs
- The risk of deal failure (with expense reimbursement and break fee implications)
- Lock-ups affecting liquidity
- Major changes in board and management structure
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors are urged to conduct their own due diligence and consult financial advisors before making any investment decisions. The information herein is based on a proposed term sheet and is subject to change pending negotiation and execution of definitive agreements.
